Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Srinivas Vourganti

Srinivas Vourganti
Srinivas Vourganti
Department of Urology
State University of New York
New York
State University of New York

Biography

Dr.Srinivas Vourganti is an Assistant Professor of Urology at State University of New York Upstate Medical University in Syracuse. He states: "Though it has been an exciting time in advancement of minimally invasive interventions, these are merely baby-steps forward. The science has not reached the patient bedside, and both overtreatment and undertreatment are rampant." It was a desire to address this need that ultimately drove him to enter in fellowship at the Urologic Oncology Branch of the National Cancer Institute. There he had the honor to collaborate with world experts in both clinical care as well as leading basic scientists and engineers to develop new ideas and bring them straight to the clinic. In addition to treating prostate cancer patients as a surgeon, he spent three years refining innovative translational imaging based platforms focused on better and more certain diagnosis, as well as minimally invasive image guided focal therapy. In his current position at SUNY Upstate Medical University, he brings this experience to provide the highest quality, cutting-edge care to his patients while minimizing the impact that treatment has on their quality of life. Most importantly, he endeavors to continue translational research to move the field forward.

Research Interest

Urologic Cancer (Prostate, Bladder, Kidney, Testis, Urethral, Adrenal Cancer), including Prostate MRI, Prostate Cancer Diagnostics, and Targeted Therapy

Top